An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients

Lung Cancer

Volumn 63, Issue 2, 2009, Pages 259-263

  Tredaniel J ^a   Becht, C ^b   Bekradda, M ^c   De Cremoux, H ^d   Alexandre, J ^e   Chomy, F ^f   Szyldergemajn, S ^c   Yataghene, Y ^g   Culine, S ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b CENTRE VAL D AURELLE   (France)

^c AAI Oncology   (France)

^d CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^e Unité d'Oncologie Médicale ^*  (France)

^f INSTITUT BERGONIÉ   (France)

^g SANOFI   (France)

Author keywords

Chemotherapy; Gemcitabine; Non small cell lung cancer; Oxaliplatin; Phase II; Survival; Vinorelbine

Indexed keywords

GEMCITABINE; NAVELBINE; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSESTHESIA; DYSGEUSIA; DYSPHAGIA; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MUCOSAL INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; OPEN STUDY; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; VINBLASTINE;

EID: 58049192384     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.05.028     Document Type: Article

References (31)

1. Jemal A., Thomas A., Murray T., et al. Cancer statistics. CA Cancer J Clin 52 (2002) 23-47
2. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995; 311:899-909.
3. Delbaldo C., Michiels S., Syz N., et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292 (2004) 470-484
4. Monnet I., Cremoux de H., Soulie P., et al. Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study. Ann Oncol 13 (2002) 103-107
5. Raymond E., Chaney S., Taamma A., et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9 (1998) 1053-1071
6. Monnet I., Brienza S., Hugret F., et al. Phase II study of oxaliplatin in poor prognosis non-small cell lung cancer (NSCLC). Eur J Cancer 34 (1998) 1124-1127
7. Monnet I., Soulié P., de Cremoux H., et al. Phase I/II Study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 19 (2001) 458-463
8. Voland C., Bord A., Peleraux A., et al. Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther 5 (2006) 2149-2157
9. Faivre S., Raymond E., Woynarowski J., et al. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 44 (1999) 117-123
10. Louvet C., André T., Lledo G., et al. Gemcitabine combined with oxaliplatin (GEMOX) combination in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 20 (2002) 1512-1518
11. O'Rourke T., Brown T., Havlin K., et al. Phase I clinical trial of difluorodeoxycytidine given as an intravenous bolus on five consecutive days. Invest New Drugs 10 (1989) 165 (abstract)
12. Brown T., O'Rourke T., Burris III H.A., et al. A phase I trial of gemcitabine (LY188011) administered intravenously every two weeks. Proc Am Soc Clin Oncol 10 (2001) 115 (abstract)
13. Comella P., Frasci G., Panza N., et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 18 (2000) 1451-1457
14. Laack E., Mende T., Durk H., et al. Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: a phase II trial. Eur J Cancer 38 (2002) 654-660
15. Niho S., Kubota K., Goto K., et al. Triplet chemotherapy with vinorelbine, gemcitabine, and cisplatin for advanced non-small cell lung cancer: a phase II study. Br J Cancer 87 (2002) 1360-1364
16. Laack E., Dickgreber N., Muller T., et al. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol 22 (2004) 2348-2356
17. Esteban E., Fra J., Fernandez Y., et al. Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non-small cell lung cancer: results of a prospective randomized phase II study. Invest New Drugs 24 (2006) 241-248
18. Frasci G., Lorusso V., Panza N., et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18 (2000) 2529-2536
19. Lorusso V., Carpagnano F., Frasci G., et al. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J Clin Oncol 18 (2000) 405-411
20. Herbst R., Lynch C., Vasconcelles M., et al. Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. Cancer Chemother Pharmacol 48 (2001) 151-159
21. Taieb J., Bonyhay L., Golli L., et al. Gemcitabine plus oxaliplatin in inoperable hepatocellular carcinoma (HCC): a comparison of two schedules. Ann Oncol (ESMO) 13 (2002) 196 (abstract)
22. Shepherd F., Abratt R., Crino L., et al. The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer. Lung Cancer 30 (2000) 117-125
23. Tempero M., Plunkett W., Ruiz van Haperen V., et al. Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 18 (1999) 273a (abstract)
24. Grunewald R., Abbruzzese J., Tarasoff P., et al. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27 (1991) 258-262
25. Abbruzzese J., Grunewald R., Weeks E.A., et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9 (1991) 491-498
26. Levi F., Misset J.L., Brienza S., et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 69 (1992) 893-900
27. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
28. Simon R. Optimal two-stage designs for Phase II clinical trials. Control Clin Trials 10 (1989) 1-10
29. Paccagnella A., Oniga F., Bearz A., et al. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study. J Clin Oncol 24 (2006) 681-687
30. Sandler A., Gray R., Perry M., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
31. Taieb J., Bonyhay L., Golli L., et al. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 98 (2003) 2664-2670